

# Immedica Pharma: Methodological note for disclosure of transfer of value (ToV) to HCP/HCO 2025

**Data year:** 2025

**Year of publication:** 2026

**This methodological note is valid for the Immedica Pharma AB operations within the Nordic and Baltic affiliate. Writer: Martin Ramström, General Manager Nordic & Baltic, Immedica Pharma AB. martin.ramstrom@immedica.com**

## Contents

1	Definitions .....	2
1.1	Recipients.....	2
1.2	Kind of ToVs .....	2
2	Disclosure's Scope.....	2
2.1	Products concerned.....	2
2.2	Company concerned.....	2
2.3	Excluded ToVs.....	2
2.4	ToVs date .....	2
2.5	Direct ToVs .....	3
2.6	Indirect ToVs.....	3
2.7	Non-monetary ToVs.....	3
2.8	ToVs in case of partial attendances or cancellation and refund .....	3
2.9	Cross-border activities .....	3
2.10	R&D.....	3
2.11	Voluntary disclosure.....	3
3	Specific considerations.....	3
3.1	Country unique identifier .....	3
3.2	Self-incorporated HCP .....	3
3.3	Multi-year agreements .....	3
3.4	Country specificities.....	3

3.5	Quality Checks .....	4
4	Data protection legal basis .....	4
4.1	Consent collection .....	4
4.2	Legitimate interests.....	4
5	Form of disclosure.....	4
5.1	Date of publication.....	4
5.2	Disclosure platform.....	4
5.3	Disclosure language .....	4
6	Disclosure financial data.....	4
6.1	Currency.....	4
6.2	VAT included or excluded .....	5
6.3	Calculation rules .....	5
7	Additional Information.....	5

# 1 Definitions

## 1.1 Recipients

HCPs in disease areas relevant to Immedica Pharma.

## 1.2 Kind of ToVs

Sweden, Denmark Norway and Finland: Speaker fees and consultancy services

Denmark and Finland: Congress registrations and travel support

# 2 Disclosure's Scope

## 2.1 Products concerned

Ravicti (glycerol phenylbutyrate), Zepcelca (lurbinectedin)

## 2.2 Company concerned

Immedica Pharma AB / Nordic Affiliate

## 2.3 Excluded ToVs

None

## 2.4 ToVs date

2025.01.01 – 2025.12.31

## **2.5 Direct ToVs**

Yes

## **2.6 Indirect ToVs**

None

## **2.7 Non-monetary ToVs**

None

## **2.8 ToVs in case of partial attendances or cancellation and refund**

None

## **2.9 Cross-border activities**

Nordic Exchange of Experiences symposia urea cycle disorders. Nordic Dieticians' Day urea cycle disorders.

## **2.10 R&D**

None

## **2.11 Voluntary disclosure**

All ToVs are disclosed

# **3 Specific considerations**

## **3.1 Country unique identifier**

## **3.2 Self-incorporated HCP**

## **3.3 Multi-year agreements**

None

## **3.4 Country specificities**

Norway and Sweden: No sponsoring allowed of HCP participation and travelling to meetings and congresses.

### **3.5 Quality Checks**

Immedica Pharma process for ToV is defined in a SOP.

## **4 Data protection legal basis**

### **4.1 Consent collection**

Consent included in agreements eg consultancy agreement.

### **4.2 Legitimate interests**

## **5 Form of disclosure**

### **5.1 Date of publication**

Denmark: Jan 31, 2026. Sweden, Norway and Finland: May 29, 2026

### **5.2 Disclosure platform**

Denmark:

- HCPs are responsible to report data to DKMA within 5 days from the event.
- Pharma companies are responsible to collect data on value transactions to HCPs and HCOs and report back to DKMA about the previous year no later than Jan. 31
- Immedica has permission to e-mail the documentation yearly to [tilknytning@dkma.dk](mailto:tilknytning@dkma.dk) due to lack of electronic company ID in Denmark

Sweden, Norway and Finland:

- On May 31 every year, Immedica Pharma publishes the ToVs for the previous year on <https://www.immedica.com/en/transparency>

### **5.3 Disclosure language**

Danish, English

## **6 Disclosure financial data**

### **6.1 Currency**

Local currency used. SEK, NOK, DKK and EUR

## **6.2 VAT included or excluded**

VAT included in costs for registrations and travels. VAT excluded in consultancy services and speaker fee.

## **6.3 Calculation rules**

# **7 Additional Information**